MOR.DE - MorphoSys AG
| Previous Close | 127.90 |
| Open | 128.60 |
| Bid | 130.10 x 1500 |
| Ask | 130.20 x 8800 |
| Day's Range | 128.50 - 130.70 |
| 52 Week Range | 79.70 - 130.70 |
| Volume | 61,890 |
| Avg. Volume | 152,014 |
| Market Cap | 4.1B |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.04 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.55 |
- ACCESSWIRE
MorphoSys AG: Corporate Calendar 2020
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR): Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2020 as follows: For a direct import of the ...
- Reuters
Chief scientist quits at Germany's Morphosys ahead of product launch
Morphosys' chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch. The group said late on Wednesday that CSO Markus Enzelberger would step down at the end of February to explore new opportunities. The shares dropped 2.1% at 0853 GMT on Thursday as one trader pointed to Enzelberger's "crucial position" at Morphosys.
- ACCESSWIRE
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific Officer (CSO), has decided to step down as CSO and member of the company's Management Board to explore new opportunities. Dr. Enzelberger will leave MorphoSys on February 29, 2020.
- ACCESSWIRE
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
IDMC recommends to increase patient number from currently 330 to 450. MARTINSRIED, GERMANY / ACCESSWIRE / November 18, 2019 / MorphoSys (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that the ongoing tafasitamab phase 3 B-MIND study has successfully passed the pre-planned, event-driven interim analysis for futility. An independent data monitoring committee (IDMC) reviewed the data and recommended to increase the number of patients from currently 330 to 450.
- ACCESSWIRE
MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice
PLANEGG/MUNICH, GERMANY and BOSTON MA / ACCESSWIRE / November 15, 2019 / MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today the opening of its new U.S. headoffice. ...
- Simply Wall St.
MorphoSys (ETR:MOR) Shareholders Have Enjoyed An Impressive 116% Share Price Gain
MorphoSys AG (ETR:MOR) shareholders might be concerned after seeing the share price drop 10% in the last quarter. But...
- Thomson Reuters StreetEvents
Edited Transcript of MOR.DE earnings conference call or presentation 30-Oct-19 1:00pm GMT
Q3 2019 Morphosys AG Earnings Call
- ACCESSWIRE
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results ...
- ACCESSWIRE
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced presentation of so far unpublished data on tafasitamab, ...
- ACCESSWIRE
MorphoSys AG Reports Third Quarter 2019 Financial Results
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG Reports Third Quarter 2019 Financial Results Conference call and webcast (in English) to be held on October 30, 2019 at 2:00pm CET ...
- ACCESSWIRE
MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced topline results from the primary analysis of the retrospective ...
- ACCESSWIRE
MorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR): Primary endpoint met: Statistically significant superior best objective ...
- ACCESSWIRE
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
NASDAQ:MOR) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, Galapagos NV, MorphoSys AG and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study.
- ACCESSWIRE
MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped
NASDAQ: MOR) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, Galapagos NV, MorphoSys AG and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study.
- Insider Monkey
Did Hedge Funds Drop The Ball On MorphoSys AG (MOR) ?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
- ACCESSWIRE
Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 21, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) will publish its first nine months' 2019 results on October 29, 2019 ...
- Thomson Reuters StreetEvents
Edited Transcript of MOR.DE earnings conference call or presentation 7-Aug-19 12:00pm GMT
Half Year 2019 Morphosys AG Earnings Call
- ACCESSWIRE
MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China
NASDAQ:MOR) and I-Mab Biopharma (I-Mab) announced today that I-Mab has received Investigational New Drug (IND) clearances from the National Medical Products Administration (NMPA) of China to expand the ongoing phase 2 and 3 clinical trials of MOR202/TJ202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma (MM), also to mainland China.
- ACCESSWIRE
MorphoSys to Present at Upcoming Investor Conferences
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 18, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences: Baader Investment Conference ...
- ACCESSWIRE
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya (R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis PLANEGG / MUNICH, GERMANY / ACCESSWIRE ...
Motley FoolMorphoSys AG (MOR) Q2 2019 Earnings Call Transcript
MOR earnings call for the period ending June 30, 2019.
- ACCESSWIRE
MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
B-MIND compares the efficacy of tafasitamab (MOR208) plus bendamustine versus rituximab plus bendamustine in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). The biomarker, which is the basis for a co-primary endpoint, is described as a low baseline peripheral blood natural killer (NK) cell count and was implemented in agreement with the FDA as an amendment of B-MIND in the first quarter of this year. Patients with a low number of NK cells (defined as 100 or fewer NK cells per microliter blood) at study entry represent approximately 50% of the overall study population and are believed to exhibit a less favorable response to anti-CD20-based therapies.
- ACCESSWIRE
MorphoSys AG Reports Second Quarter 2019 Financial Results
MUNICH, GERMANY / ACCESSWIRE / August 6, 2019 / MorphoSys AG Reports Second Quarter 2019 Financial Results Conference call and webcast (in English) to be held on August 7, 2019 at 2:00pm CEST (1:00pm BST/8:00am ...
- ACCESSWIRE
MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 6, 2019 / MorphoSys AG (FSE:MOR) (Prime Standard Segment:MDAX) (Prime Standard Segment:TecDAX) (NASDAQ:MOR) today announced its intention to submit a Marketing ...
- ACCESSWIRE
Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 25, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first six months' 2019 results on August 6, 2019 at 10:00pm ...
